The content of this report will be updated with the latest scenarios based on the global COVID-19 Pandemic
The Asia Pacific Genetic Testing Market would witness market growth of 12.7% CAGR during the forecast period (2019-2025).
The growing focus on regulating and raising awareness about genetic testing by governments of different nations has resulted in quicker adoption of these tests worldwide. Increasing R&D financing has established a strong entry obstacle for new industry respondents, along with the solid market presence of significant players existing in the market. Product design innovation, performance enhancement, and strong distribution partnerships are crucial parameters to maintain a competitive business edge.
Countries like China, and Japan, are rapidly adapting direct to consumer genetic testing kits. With this increasing adoption of novel technologies, awareness programs, and reduced costs, the market for DTC-GT kits is expected to observe a major boost over the years to come. Furthermore, the untapped countries like India and Australia, and other progressing countries, show possibilities of providing profitable growth opportunities to market players who are looking to establish their base in the genetic testing market.
Based on Type, the market is segmented into Predictive and Presymptomatic Carrier Testing, Prenatal and Newborn Testing, Diagnostic Testing, Pharmacogenomic Testing, and Other Types. Based on Technology, the market is segmented into Cytogenetic Testing, Biochemical Testing and Molecular Testing. Based on Application, the market is segmented into Cancer Diagnosis, Genetic Disease Diagnosis, Cardiovascular Disease Diagnosis and Other Applications. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Myriad Genetics, Inc., Empire Genomics LLC, Bio-Rad Laboratories, Inc., Novartis AG, Agilent Technologies, Inc., Thermo Fisher Scientific, Inc., Qiagen N.V., Illumina, Inc., Danaher Corporation, and Abbott Laboratories (Abbott Laboratories Molecular, Inc.).
Scope of the Study
- Predictive and Presymptomatic Carrier Testing
- Prenatal and Newborn Testing
- Diagnostic Testing
- Pharmacogenomic Testing
- Other Types
- Cytogenetic Testing
- Biochemical Testing and
- Molecular Testing
- Cancer Diagnosis
- Genetic Disease Diagnosis
- Cardiovascular Disease Diagnosis and
- Other Applications
- South Korea
- Rest of Asia Pacific
- Myriad Genetics, Inc.
- Empire Genomics LLC
- Bio-Rad Laboratories, Inc.
- Novartis AG
- Agilent Technologies, Inc.
- Thermo Fisher Scientific, Inc.
- Qiagen N.V.
- Illumina, Inc.
- Danaher Corporation
- Abbott Laboratories (Abbott Laboratories Molecular, Inc.)
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free